It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
While macrophage phagocytosis is an immune defense mechanism against invading cellular organisms, cancer cells expressing the CD47 ligand send forward signals to repel this engulfment. Here we report that the reverse signaling using CD47 as a receptor additionally enhances a pro-survival function of prostate cancer cells under phagocytic attack. Although low CD47-expressing cancer cells still allow phagocytosis, the reverse signaling delays the process, leading to incomplete digestion of the entrapped cells and subsequent tumor hybrid cell (THC) formation. Viable THCs acquire c-Myc from parental cancer cells to upregulate both M1- and M2-like macrophage polarization genes. Consequently, THCs imitating dual macrophage features can confound immunosurveillance, gaining survival advantage in the host. Furthermore, these cells intrinsically express low levels of androgen receptor and its targets, resembling an adenocarcinoma-immune subtype of metastatic castration-resistant prostate cancer. Therefore, phagocytosis-generated THCs may represent a potential target for treating the disease.
The CD47/SIRPα axis is well known to mediate immune escape by promoting cancer resistance to phagocytosis. Here the authors show that low CD47-expressing prostate cancer cells still allow phagocytosis but the process is incomplete leading to the formation of macrophage:tumor hybrid cells with immune evasive and pro-metastatic properties.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


















1 University of Texas Health Science Center, Department of Molecular Medicine, San Antonio, USA (GRID:grid.468222.8)
2 Ditmanson Medical Foundation Chia-Yi Christian Hospital, Department of Pathology, Chiayi, Taiwan (GRID:grid.413878.1) (ISNI:0000 0004 0572 9327)
3 National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Department of Pathology, Tainan, Taiwan (GRID:grid.412040.3) (ISNI:0000 0004 0639 0054)
4 University of Texas Health Science Center, Department of Urology, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Mays Cancer Center, San Antonio, USA (GRID:grid.468222.8)
5 University of Texas Health Science Center, Department of Pathology and Laboratory Medicine, San Antonio, USA (GRID:grid.468222.8)
6 University of Texas Health Science Center, Department of Molecular Medicine, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Department of Urology, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Mays Cancer Center, San Antonio, USA (GRID:grid.468222.8)
7 University of Texas Health Science Center, Department of Molecular Medicine, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Mays Cancer Center, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Department of Medicine, San Antonio, USA (GRID:grid.468222.8)
8 University of Texas Health Science Center, Department of Molecular Medicine, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Biobehavior Laboratory, School of Nursing, San Antonio, USA (GRID:grid.468222.8)
9 University of Texas Health Science Center, Department of Molecular Medicine, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Mays Cancer Center, San Antonio, USA (GRID:grid.468222.8)